DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



An Efficacy and Tolerability Study of Topiramate in Participants With Migraine

Information source: Janssen Korea, Ltd., Korea
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Migraine

Intervention: Topiramate Standard (Drug); Topiramate Slow (Drug); Propranolol booster (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Janssen Korea, Ltd., Korea

Official(s) and/or principal investigator(s):
Janssen Korea, Ltd., Korea Clinical Trial, Study Director, Affiliation: Janssen Korea, Ltd., Korea

Summary

The purpose of this study is to investigate the adequacy (reasonably good) of topiramate therapy (medicine or medical care given to a participant for a disease or condition) in prevention of migraine (type of severe headache that occurs periodically and is often associated with nausea, vomiting, and constipation or diarrhea) by comparing standard titration (slow increase in drug dosage, guided by patient's responses) therapy to slow titration therapy and slow titration therapy boosted by the concurrent use of propranolol in participants with migraine with or without aura (having to do with the ear) for more than or equal to 2 attacks per month.

Clinical Details

Official title: Adequate Therapy of Topiramate in Migraine

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Primary outcome: Percentage Decrease in Migraine Episodes

Secondary outcome:

Change From Baseline in Migraine Frequency at Week 6

Change From Baseline in Migraine Disability Assessment (MIDAS) Score at Week 6

Change From Baseline in Visual Analogue Scale (VAS) Score at Week 6

Detailed description: This is a prospective (study following participants forward in time), single-blind (Physician does not know the intervention), randomized (study drug assigned by chance) and comparative multi-center (conducted in more than 1 center) study to assess appropriate administration methods with topiramate preventive therapy in participants with migraine. The study consists of 3 periods: Screening period (4 weeks), Treatment period consisting of 2 titration periods (3 weeks each) and Maintenance period (4 weeks). During Screening period, after the diagnosis of participants' headache, symptoms and severity of migraine will be investigated through a headache diary and participants will be selected for treatment period. In the treatment period, the selected participants will be randomly assigned to either of the 3 topiramate therapy: 'topiramate standard group', 'topiramate slow group',

and 'topiramate slow plus propranolol (booster) group'. In the 'topiramate standard group' -

participants will receive an initial dose of topiramate 25 milligram (mg) once daily and the dose of topiramate will be increased by 25 mg per day at an interval of 1-week up to the target dose of 50 mg to 100 mg up to Week 6; and a maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion. In 'topiramate slow

group' - participants will start with an initial dose of 25 mg once daily and the dose will

be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week

10 as per Physician's discretion. In 'topiramate slow plus propranolol (booster) group' -

participants will follow the same dosage regimen as in the 'topiramate slow group' along with concurrent administration of booster dose of propranolol 80 mg once daily (40 mg each time in the morning and in the evening) for 6 weeks. The participants will primarily be evaluated for reduction in migraine frequency between Week 7 and 10 using a headache diary questionnaire maintained by them. Participants' quality of life will be assessed using Migraine Disability Assessment (MIDAS) score and intensity of pain in migraine will be assessed using Visual Analogue Scale (VAS). Participants' safety will be monitored throughout the study.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Particpants who have signed the consent form

- Participants who have 3 to 14 episodes of migraine a month

- Participants whose duration of migraine is at least 6 months

- Participants who can read and understand the migraine disability assessment (MIDAS)

questionnaire

- Female Participants who are using an appropriate contraception method or have

negative pregnancy test results Exclusion Criteria:

- Participants whose headache attacks at Baseline or during the study period are

assumed to be caused by a drug withdrawal syndrome

- Participants whose migraine has appeared first at over 50 years of age

- Participants who have taken anticonvulsants (valproic acid, gabapentin), beta

adrenergic blockers (propranolol) and calcium antagonists (sibelium, verapamil, diltiazem) or topiramate or propranolol within the last 8 weeks

- Participants with progressive neurological (pertaining to the nervous system)

disorder

- Participants with severe renal (pertaining to the kidneys) disorder, hepatic

(pertaining to the liver) failure or diabetes (disorder in which there is decreased insulin in the body or the body's insulin is not effective, resulting in high blood sugar, increased thirst and urine, and many other side effects) or with the history of renal calculus

Locations and Contacts

Busan, Korea, Republic of

Daegu, Korea, Republic of

Kwangjoo, Korea, Republic of

Kyunggi-Do, Korea, Republic of

Seoul, Korea, Republic of

Uijeongbu, Korea, Republic of

Additional Information

Starting date: July 2006
Last updated: August 14, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017